ROCKVILLE, Maryland, Oct. 12, 2004 (PRIMEZONE) -- Cytomedix, Inc. (OTCBB:CYME) today announced it is scheduled to make a presentation on Tuesday, October 26, 2004, at 4:55 p.m. Eastern time at Rodman & Renshaw's Techvest 6th Annual Healthcare Conference to be held in New York City at the Waldorf-Astoria.
Kshitij Mohan, Ph.D., Cytomedix's chief executive officer, will provide an overview of the company's unique approach to the treatment of chronic wounds utilizing its propriety AutoloGel(tm) System, as well as the company's progress regarding its intellectual property licensing initiatives and ongoing clinical trial. A link to the webcast of the presentation will be available through the company's web site at www.cytomedix.com.
In recent months the company has received favorable rulings from United States District Courts in Illinois and Massachusetts related to patent infringements of the company's platelet-derived therapies for treating wounds and other damaged tissue.
The company is currently conducting a FDA-approved prospective, randomized, double-blind, controlled study for the treatment of chronic diabetic foot ulcers at over a dozen premier sites throughout the United States.
Cytomedix, Inc. is a biotechnology company specializing in processes and products derived from autologous platelet releasates. The current product offering is the AutoloGel(tm) System, which produces an autologous platelet gel composed of multiple growth factors and fibrin matrix for treatment of chronic wounds. Cytomedix is working with healthcare providers to offer an advanced therapy at the point-of-care in multiple settings. Additional information is available at the company's website at www.cytomedix.com.